Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycopyrrolate inhalation - Chiesi

Next Previous
Drug Profile

Glycopyrrolate inhalation - Chiesi

Alternative Names: CHF-5259; Extrafine glycopyrronium bromide pMDI

Latest Information Update: 10 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi
  • Class Antiasthmatics; Antispasmodics; Antiulcers; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Sep 2022 Pharmacodynamics data from preclinical trial in Asthma presented at the 32nd Annual Congress of the European Respiratory Society (ERS-2022)
  • 17 May 2019 Efficacy and safety data from the phase II GLIMMER trial in Chronic obstructive pulmonary disease presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
  • 06 Jun 2018 Chiesi completes a phase II trial in Chronic obstructive pulmonary disease in USA (Inhalation) (NCT03084796)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top